… presented for patients who achieved complete remission (CR) and complete remission
without platelet recovery (CR p ) after 2 doses of gemtuzumab ozogamicin. Pooled results from 3 …

… approval for the use of gemtuzumab ozogamicin (GO) in … a 30% response rate (including
complete response [CR] and CR … , 61 years) with relapsed AML noted a response rate of 26%, …

… The results failed to show any improvement in complete response rate, RFS, or OS rates
when GO was added. Moreover, a significantly higher mortality rate of 5.5% was reported in the …

… of gemtuzumab ozogamicin did not increase the proportion of patients achieving complete
remission with or without complete … However, the addition of gemtuzumab ozogamicin …

… demonstrated complete response (CR) or complete response … approval process, gemtuzumab
ozogamicin was allowed … that phase III studies be completed as planned to prove benefit …

… Duration of second complete remission in patients with acute myeloid leukemia treated
with chemotherapy: a retrospective single-center study. Ann Hematol. 1996; 72:216-22. …

… Patients with a complete remission (CR) or CR with incomplete platelet recovery (CRp)
after induction treatment received 2 courses of consolidation, including DNR and AraC with or …

… The complete response (CR) rate after relapse is around 25%, with 11% of patients still
alive after 5 years. The efficacy and toxicity of fractionated gemtuzumab ozogamicin (fGO; 3 mg/…

… The complete response (CR) rate with full recovery of hematopoiesis was 16%. A subset
of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance …

… CONCLUSION: Administration of the antibody-targeted chemotherapy agent Mylotarg to
patients with CD33-positive AML in first relapse induces complete remissions with what appears …